Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lais Parietaria sublingual immunotherapy in preseasonal versus coseasonal dosing for Parietaria-induced allergic rhinoconjunctivitis
2008-007657-12Phase 3Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Mar 2009
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of parietaria monomeric carbamylated allergoid in seasonal allergic rhinitis (SAR), allergic conjunctivitis (AC) and allergic asthma (3 arms), sponsored by Lofarma S.p.A. Primary endpoint: Efficacy comparison of preseasonal versus coseasonal Lais Parietaria versus placebo. Started Mar 2009; status: completed.
02
Drugs
parietaria monomeric carbamylated allergoid
03
Conditions
seasonal allergic rhinitis (SAR)allergic conjunctivitis (AC)allergic asthma
Beyond the preview
Go deeper on 2008-007657-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007657-12.